Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2026)

Akebia Therapeutics (AKBA) has 8 years of Non-Current Debt data on file, last reported at $36.4 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $36.4 million, down 21.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.4 million (down 21.75% YoY), and the FY2025 annual result was $48.2 million, up 24.7% from the prior year.
• Non-Current Debt eased to $36.4 million in Q1 2026 per AKBA's latest filing, from $48.2 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $48.2 million in Q4 2025 and troughed at $17.2 million in Q4 2023.
• A 5-year average of $35.8 million and a median of $37.2 million in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2023 and 2024: Non-Current Debt slumped 49.58% in 2023, then surged 125.18% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $34.1 million in 2022, then tumbled by 49.58% to $17.2 million in 2023, then jumped by 125.18% to $38.7 million in 2024, then increased by 24.7% to $48.2 million in 2025, then decreased by 24.57% to $36.4 million in 2026.
• Business Quant data shows AKBA's Non-Current Debt at $36.4 million in Q1 2026, $48.2 million in Q4 2025, and $47.6 million in Q3 2025.